In Vitro Activities of Eight Antifungal Drugs against 55 Clinical Isolates of Fonsecaea spp-Reference-Cited by-同舟云学术

In Vitro Activities of Eight Antifungal Drugs against 55 Clinical Isolates of Fonsecaea spp

Published:2010-04 Issue:4 Volume:54 Page:1636-1638
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Najafzadeh Mohammad J.¹²³,Badali Hamid¹²⁴,Illnait-Zaragozi Maria Teresa⁵,De Hoog G. Sybren¹²⁶,Meis Jacques F.⁷

Affiliation:

1. CBS-KNAW Fungal Biodiversity Centre, Utrecht, The Netherlands

2. Institute for Biodiversity and Ecosystem Dynamics, University of Amsterdam, Amsterdam, The Netherlands

3. Department of Parasitology and Mycology, Mashhad University of Medical Sciences, Mashhad, Iran

4. Department of Medical Mycology and Parasitology, School of Medicine/Molecular and Cell Biology Research Center, Mazandaran University of Medical Sciences, Sari, Iran

5. Department of Mycology, Tropical Medicine Institute Pedro Kouri, Havana, Cuba

6. Peking University Health Science Center, Research Center for Medical Mycology, Beijing, China

7. Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands

Abstract

ABSTRACT The in vitro activities of eight antifungal drugs against clinical isolates of Fonsecaea pedrosoi ( n = 21), Fonsecaea monophora ( n = 25), and Fonsecaea nubica ( n = 9) were tested. The resulting MIC 90 s for all strains ( n = 55) were as follows, in increasing order: posaconazole, 0.063 μg/ml; itraconazole, 0.125 μg/ml; isavuconazole, 0.25 μg/ml; voriconazole, 0.5 μg/ml; amphotericin B, 2 μg/ml; caspofungin, 2 μg/ml; anidulafungin, 2 μg/ml; and fluconazole, 32 μg/ml.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01655-09

Reference21 articles.

1. Andrade, T. S., L. G. Castro, R. S. Nunes, V. M. Gimenes, and A. E. Cury. 2004. Susceptibility of sequential Fonsecaea pedrosoi isolates from chromoblastomycosis patients to antifungal agents. Mycoses47:216-221.

2. Attapattu Maya, C. 1997. Chromoblastomycosis—a clinical and mycological study of 71 cases from Sri Lanka. Mycopathologia137:145-151.

3. Bonifaz, A., E. Martinez-Soto, E. Carrasco-Gerard, and J. Peniche. 1997. Treatment of chromoblastomycosis with itraconazole, cryosurgery, and a combination of both. Int. J. Dermatol.36:542-547.

4. Bonifaz, A., E. Carrasco-Gerard, and A. Saul. 2001. Chromoblastomycosis: clinical and mycologic experience of 51 cases. Mycoses44:1-7.

5. Bonifaz, A., V. Paredes-Solis, and A. Saul. 2004. Treating chromoblastomycosis with systemic antifungals. Expert Opin. Pharmacother.5:247-254.

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In vitro evaluation of antifungal combinations against neurotropic dematiaceous fungi associated with primary cerebral phaeohyphomycosis;Microbiology Spectrum;2024-08-06

2. Molecular Identification of Fonsecaea monophora, Novel Agent of Fungal Brain Abscess;Emerging Infectious Diseases;2024-06

3. Resazurin to determine the minimum inhibitory concentration on antifungal susceptibility assays for Fonsecaea sp. using a modified EUCAST protocol;Brazilian Journal of Microbiology;2024-03-04

4. Antifungal Susceptibility and Biological Characteristics of Fonsecaea monophora Causing Cerebral Phaeohyphomycosis in Jinhua, China;Infection and Drug Resistance;2023-11

5. Repurposing Benzimidazoles against Causative Agents of Chromoblastomycosis: Albendazole Has Superior In Vitro Activity Than Mebendazole and Thiabendazole;Journal of Fungi;2023-07-16